Application of pharmacogenomics in clinical pharmacology

被引：27

作者：

Huang, SM ^{[1
]}

Goodsaid, F ^{[1
]}

Rahman, A ^{[1
]}

Frueh, F ^{[1
]}

Lesko, LJ ^{[1
]}

机构：

[1] US FDA, Off Clin Pharmacol & Biopharmaceut, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA

来源：

TOXICOLOGY MECHANISMS AND METHODS | 2006年 / 16卷 / 2-3期

基金：

美国国家科学基金会;

关键词：

pharmacogenomics application; clinical pharmacology;

D O I：

10.1080/15376520600558333

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

Many factors can affect a patient's response to a drug. These include intrinsic factors such as age, gender, race/ethnicity, genetics, disease states, organ dysfunctions, and other physiological changes, including pregnancy, lactation, and extrinsic factors such as smoking, diet ( food, juice, dietary supplements), and concomitant medications (ICH E5, 1998 and 2004). The interplay of genotypes of the enzymes, transporters and receptors, among other factors ( such as concomitant medications and disease states), can affect the risk/benefit ratio for individual patients. This commentary discusses when the genomic information should be obtained during drug development and when it is to be assimilated into labeling and standards of care that can be used to "individualize" drug therapy and become one of the pillars of "personalized medicine."

引用

页码：89 / 99

页数：11